Have a question or topic idea for The Life Science Report? Submit it here.
The Optimism of Bispecific Antibodies
Guests: Pete Bak and Christian Thienel
Length: 26 minutes
Airdate: November 1, 2024
The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific antibody ivonescimab to treat non-small cell lung cancer that has captured the industry writ large encouraged us to revisit the topic.
To date, there have been ten bispecific antibody approvals in oncology, seven of which are for hematological malignancies. Recently, there has been more traction in development pipelines for solid tumors. Most bispecific antibody approvals are currently or projected to be above the $1M annual revenue threshold.
Podcast topics include:
The biologics of a bispecific antibody
The benefits of a bispecific antibody compared to autologous therapies
The buzz around Akeso and Summit’s PD-1 VEGF bispecific antibody asset
The broad state of bispecifics in approved products and development pipelines
The potential of trispecifics, bispecific conjugates and beyond
You can listen to previous episodes here or submit your inquiries here.
Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.
Subscribe:
Apple Podcasts | Libsyn | Spotify | Stitcher